Direct Biologics Initiates Patient Enrollment in the Phase II EXIT COVID-19 Clinical Trial
EXIT COVID-19 has initiated enrollment of 75 COVID-19 patients with moderate-to-severe ARDS at multiple research sites across the U.S. The primary efficacy endpoints will be all-cause mortality and median days to recovery.